Plain-English translation of NCT07589634 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called , given as a single dose before starting treatment, can prevent or reduce a serious side effect called cytokine release syndrome. Cytokine release syndrome is an acute inflammatory reaction that can cause flu-like symptoms, fever, and fatigue during cancer treatment. About half the participants will receive the preventive medication while the other half receive a placebo (a dummy treatment) to see which approach works better.
is a new treatment for multiple myeloma, but it can trigger an inflammatory reaction in the body that causes uncomfortable or dangerous symptoms. Researchers want to see if giving this preventive medication beforehand can protect patients from these side effects, making the new cancer treatment safer and more tolerable.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the preventive medication or a placebo injection before starting treatment. You'll continue the cancer medication for a set period or until your disease progresses or side effects become too severe. The study will monitor you closely for 28 days after starting treatment to track whether you develop the inflammatory side effect, and you'll have regular blood tests and check-ins with your medical team throughout your participation.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States
Argentina
Australia